Skip to main content

Table 1 Patient demographics and immunosuppressive and antibiotic regimens

From: The urinary microbiome shows different bacterial genera in renal transplant recipients and non-transplant patients at time of acute kidney injury – a pilot study

  RTX (n = 21) nRTX (n = 9) p-value
Age, years 56 ± 16.0 62 ± 20 0.39
Sex
 Male 13 3 0.24
 Female 8 6 0.24
AKI stage
 Stage 1 9 3 0.70
 Stage 2 11 3 0.44
 Stage 3 1 3 0.07
sCr (mg/dL) 3.0 ± 1.8 4.1 ± 3.9 0.29
BUN (mg/dL) 46.0 ± 20.7 57.8 ± 35.2 0.26
Median time after RTX (month) 5 N/A  
Immunosuppression
 TAC + mycophenolate+steroids 16 0  
 TAC + steroids 1 0  
 CYA + mycophenolate+steroids 1 0  
 CYA + mycophenolate 1 0  
 TAC + azathioprine+steroids 1 0  
 Sirolimus+mycophenolate+steroids 1 0  
Antibioticsa
 Beta-lactam + beta-lactamase inhibitor 3 0 0.53
 Piperacillin/tazobactam 5 1 0.64
 Cephalosporin 4 0 0.29
 Metronidazole 2 0 1
 Fluoroquinolone 0 1 0.3
  1. CYA Cyclosporine A, eGFR estimated glomerular filtration rate, sCr serum creatinine, BUN blood urea nitrogen, TAC tacrolimus, N/A not applicable, ±SD standard diviation; a indicates antibiotic intake prior or at time of AKI